terminal

Clathrin-IN-1 is a inhibitor of clathrin, and inhibits clathrin-mediated endocytosis (CME) by associating with the terminal domain of clathrin. It has the potential for anti-cancer research.

Oxytocin C-terminal tripeptide Acetate is the C-terminal tripeptide of Oxytocin.Oxytocin is a mammalian neuropituitary hormone, a ligand for the oxytocin receptor.

Fas C-Terminal Tripeptide Acetate shows inhibitory activity of Fas/FAP-1 binding.

NEP(1-40), N-terminal uncapped, is an analog of NEP(1-40) without acetylation at the N-terminus. NEP(1-40) acts as a peptide antagonist of the Nogo-66 receptor (NgR).

Cemdisiran, an investigational N-acetylgalactosamine-conjugated RNAi (RNA interference) agent with terminal sugar modification, is a small interfering RNA (siRNA) designed to specifically target and suppress the C5 mRNA, thereby reducing the liver's production of the complement component C5 [1].

Sphistin Synthetic Peptide (12-38, Fitc in N-Terminal-Fluorescently Labeled Peptide) represents truncated fragments of the parent peptide, characterized by an N-terminal fluorescent label (Fitc).

Amyloid precursor c-terminal peptide has the amino acid sequence Gly-Tyr-Glu-Asn-Pro-Thr-Tyr-Lys-Phe-Phe-Glu-Gln-Met-Gln-Asn. APP is best known as the precursor molecule whose proteolysis generates beta-amyloid (Aβ), a 37 to 49 amino acid peptide whose am

Terminal deoxyribonucleotidyltransferase (TdT) catalyzes the addition of deoxyribonucleotide triphosphates to the 3' hydroxyl terminus of a DNA chain and introduces N regions at gene segment junctions during V(D)J recombination. It is expressed in immature, pre-B, and pre-T lymphocytes, as well as in acute lymphoblastic leukemia/lymphoma cells.

Leu-enkephalin, an endogenous peptide consisting of five amino acids, functions as an agonist at opioid receptors. The N-terminally acetylated form of this compound is known as N-terminally acetylated Leu-enkephalin.

N-terminally acetylated Endomorphin-1 acetate (Ac-L-Tyr-L-Pro-L-Trp-L-Phe-CONH2) is a modified Endomorphin-1.

Polysacharide of Terminalia chebula is a natural product that can be used in related research in the field of life sciences. Its product number is TN8918.

Terminaline is a compound isolated from Sarcococca saligna. It exhibits immunosuppressive properties by inhibiting T cell proliferation and the production of IL-2. In vivo, Terminaline alleviates liver damage induced by CCl4, demonstrating effective hepatoprotective activity.

N-terminally acetylated Endomorphin-1 is a modified Endomorphin-1.

N-terminally acetylated Leu-enkephalin is the N-terminally acetylated form of Leu-enkephalin.

C-Terminally encoded peptide 1 (CEP1) is a small secreted peptide hormone involved in cell signaling, which regulates plant growth and responses to abiotic stress. It is applicable in research focused on plant growth and development.

Magrolimab (Hu5F9-G4) is a humanized anti-CD47 IgG4 monoclonal antibody that exhibits antitumor activity by blocking CD47 and binding primarily to the N-terminal pyroglutamate of CD47. It can be used in combination with other compounds for the treatment of recurrent myeloma.

Z-VAD(OMe)-FMK is a pan-caspase inhibitor with irreversible properties; Z-VAD(OMe)-FMK is also an inhibitor of ubiquitin C terminal hydrolase L1 (UCHL1), which is irreversibly modified by targeting the UCHL1 active site.

AZD0780 (EX-A6975, PCSK9-IN-12) is an orally active PCSK9 inhibitor with high affinity for PCSK9 (Kd < 200 nM). It binds to a specific pocket in the C-terminal domain of PCSK9 without affecting the PCSK9–LDLR interaction. AZD0780 blocks the lysosomal trafficking of the PCSK9–LDLR complex and prevents PCSK9-induced LDLR degradation, making it useful for studies related to hypercholesterolemia.

740 Y-P acetate (740YPDGFR acetate) is a potent and cell-permeable PI3K activator.740 Y-P acetate tends to bind to GST fusion proteins containing the N- and C-terminal SH2 structural domains of p85, but not to GST alone.

Debio 0932 (CUDC-305) is a heat shock protein 90 (Hsp90) inhibitor that targets the n-terminal atp-binding pocket to promote apoptosis, and has the advantage of being orally available and able to cross the blood-brain barrier (BBB) for the treatment of cancers such as non-small-cell lung cancer (NSCLC) and neuroblastoma.

Ralaniten (EPI-002) is a potent, specific, and orally active antagonist of the androgen receptor N-terminal structural domain (AR-NTD), inhibiting AR transcriptional activity with an IC50 value of 7.4 μM. Ralaniten exhibits anticancer activity and is used to study desmoplasia-resistant prostate cancer (CRPC).

ZEN-3694 (ZEN 3694) is a bromo-structural domain extra-terminal inhibitor (BETi) with activity in androgen signaling inhibitor (ASI) resistance models and can be used in combination with enzalutamide to study metastatic desmoplasia-resistant prostate cancer.

MTOB (α-keto-γ-Methylthiobutyric acid) is a substrate for c-terminal binding protein (CtBP) that interferes with the carcinogenic activity of CtBP in cell culture and mice. It also actively regulates TCF-4 signaling, leading to cancer stem cell (CSC) growth and self-renewal.

Ralaniten triacetate (EPI-506), a precursor of Ralaniten, is a first-of-its-kind, orally active androgen receptor N-terminal structural domain (AR-NTD) inhibitor with anticancer activity and can be used to study prostate and breast cancer.